Stockton, David W.
Kishnani, Priya
van der Ploeg, Ans
Llerena, Juan Jr.
Boentert, Matthias
Roberts, Mark
Byrne, Barry J.
Araujo, Roberto
Maruti, Sonia S.
Thibault, Nathan
Verhulst, Karien
Berger, Kenneth I.
Funding for this research was provided by:
Sanofi Genzyme
Article History
Received: 22 January 2020
Revised: 15 May 2020
Accepted: 19 May 2020
First Online: 10 June 2020
Compliance with ethical standards
:
: David W. Stockton received research support from Sanofi Genzyme; received consulting fees from Sanofi Genzyme and Takeda; received travel reimbursement from Sanofi Genzyme; is a member of the Pompe Registry Scientific Advisory Board. Priya Kishnani received research/grant support from Sanofi Genzyme, Shire Pharmaceuticals, Amicus, Alexion and Pfizer, Ultragenyx, Selecta Bio, and Valerion; received consulting fees and/or honoraria from Sanofi Genzyme, Alexion, Amicus, AskBio, Baebies, and Shire; and is a member of advisory boards for Sanofi Genzyme (the International Collaborative Gaucher Group [ICGG] Gaucher Registry and the Pompe Registry Scientific Advisory Board), Baebies, Amicus, Alexion, and Shire. Ans van der Ploeg has been an advisor for Sanofi Genzyme, Amicus Therapeutics, Biomarin, Ultragenix, Sarepta, Audentes, and Spark Therapeutics under agreements between these companies and Erasmus MC, University Medical Center. Juan Llerena, Jr., received consulting fees from Sanofi Genzyme and BioMarin; and is a member of the Pompe Registry Scientific Advisory Board. Matthias Boentert received research support from Sanofi Genzyme and Lӧwenstein Medical; received consulting fees and honoraria from Sanofi Genzyme; received travel reimbursement from Sanofi Genzyme; and is a member of a speaker’s bureau for Sanofi Genzyme, UCB, and Löwenstein Medical. Mark Roberts received research support from Amicus; received consulting fees, honoraria, and travel reimbursement from Sanofi Genzyme, BioMarin, and Amicus; has received royalties from NIL; is a member of a speaker’s bureau for NIL; and is a member of the Pompe Registry Scientific Advisory Board. Barry J. Byrne received research support from Sanofi Genzyme and Amicus; is a member of the Pompe Registry Scientific Advisory Board. Roberto Araujo is an employee of Sanofi Genzyme. Sonia S. Maruti was an employee of Sanofi Genzyme at the time of the analysis and the development of the manuscript. Nathan Thibault is an employee of Sanofi Genzyme and is a Sanofi stockholder. Karien Verhulst is an employee of Sanofi Genzyme and owns shares of Sanofi. Kenneth I. Berger received research support from Sanofi Genzyme and BioMarin; received consulting fees, honoraria and/or travel reimbursement from Sanofi Genzyme, BioMarin Pharmaceutical, Amicus Therapeutics, Valerion Therapeutics, and Spark Therapeutics; is a member of advisory boards for Sanofi Genzyme and BioMarin.
: Each independent site is responsible for obtaining patients’ informed written consent to submit their health information to the Pompe Registry, and to use and disclose this information in aggregate analyses. The Registry protocol, informed consent form, and any locally required authorization documents to send patient information to the Registry are reviewed and approved by the local fully constituted Institutional Review Board (IRB) or Independent Ethics Committee (IEC) unless the site provides the Registry with documentation that approval is not required or has been waived by a particular IRB/IEC.